Curated News
By: NewsRamp Editorial Staff
October 06, 2025
NeuroOne Reports Record $9.1M Revenue, 163% Growth in FY2025
TLDR
- NeuroOne's revenue surged 163% to $9.1 million, positioning investors for growth in the neurological device market with their expanding OneRF technology platform.
- NeuroOne achieved $9.1 million in preliminary product revenue for fiscal 2025, driven by increased adoption of their OneRF Ablation system for epilepsy treatment.
- NeuroOne's technology improves surgical outcomes for epilepsy patients, advancing neurological care and enhancing quality of life for those with seizure disorders.
- NeuroOne's OneRF system treats epilepsy through minimally invasive brain ablation, showcasing medical innovation that transforms neurological disorder treatment approaches.
Impact - Why it Matters
This development represents significant progress in neurological treatment technology that could transform care for millions suffering from epilepsy and other neurological disorders. The substantial revenue growth indicates strong market adoption of NeuroOne's minimally invasive ablation system, suggesting healthcare providers are increasingly embracing advanced technologies that offer improved patient outcomes. For patients with treatment-resistant epilepsy, this technology provides new hope for effective intervention with potentially fewer complications than traditional surgical approaches. The financial success also signals investor confidence in neurological medical technology, which could accelerate further innovation and competition in a field that has seen limited treatment advancements in recent decades. As neurological disorders affect approximately 1 billion people worldwide, breakthroughs in minimally invasive treatments could substantially reduce healthcare costs while improving quality of life for patients and their families.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a pioneering medical technology company focused on neurological disorders, has announced remarkable preliminary unaudited product revenue results for fiscal year 2025. The company expects total product revenue to reach a record $9.1 million, representing a staggering 163% increase compared to the $3.5 million reported in fiscal 2024. This explosive growth was primarily driven by expanded customer adoption and positive clinical outcomes with the company's innovative OneRF® Ablation system, specifically designed for patients suffering from seizures associated with epilepsy. CEO Dave Rosa emphasized that the company is well-positioned to expand use of the OneRF technology platform, signaling confidence in future growth prospects. The company also reported preliminary cash and cash equivalents of $6.6 million as of September 30, 2025, providing financial stability for continued operations and development.
The company has scheduled a virtual investor webinar through NEWMEDIAWIRE to discuss these impressive results and provide comprehensive business updates. The event, scheduled for October 7, 2025, will feature CEO Dave Rosa providing an overview of the business model and recent milestone achievements, while CFO Ron McClurg will deliver a detailed financial overview. Interested parties can access the presentation via the NMTC Virtual Webinar Link, which includes both dial-in options and webcast access. The webinar will be followed by a question-and-answer session, allowing investors and stakeholders to engage directly with company leadership. A playback of the call will be available through October 21, 2025, ensuring broader accessibility for those unable to attend the live event.
NeuroOne's technology portfolio represents a significant advancement in neurological care, focusing on minimally invasive and high-definition solutions for EEG recording, brain stimulation, and ablation procedures. The company's innovative approaches target various neurological conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain resulting from failed back surgeries. Beyond these core applications, NeuroOne may pursue expansion into other therapeutic areas such as depression, mood disorders, pain management, incontinence, high blood pressure, and artificial intelligence applications. The company maintains an informative online presence at nmtc1.com, where stakeholders can find additional information about their groundbreaking medical technologies and treatment approaches that aim to improve patient outcomes while reducing procedural costs.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne Reports Record $9.1M Revenue, 163% Growth in FY2025
